Endothelial Progenitor Cells in Autoimmune Disorders
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature..
Circulating endothelial progenitor cells (EPCs) were first described in 1997 by Asahara et al. as "putative endothelial cells" from human peripheral blood. The study of endothelial progenitors is also intensifying in several pathologies associated with endothelial damage, including diabetes, myocardial infarction, sepsis, pulmonary arterial hypertension, obstructive bronchopneumopathy and transplantation. EPCs have been studied in several autoimmune diseases with endothelial involvement such as systemic lupus erythematosus, thrombotic thrombocytopenic purpura, antineutrophil cytoplasmic antibodies, vasculitis, rheumatoid arthritis, Goujerot-Sjögren and antiphospholipid syndrome. Factors involved in endothelial damage are due to overexpression of pro-inflammatory cytokines and/or autoantibodies. Management of these pathologies, particularly the long-term use of glucocorticoids and methotrexate, promote atherosclerosis. A lack of standardized assessment of the number and function of EPCs represents a serious challenge for the use of EPCs as prognostic markers of cardiovascular diseases (CVD). The objective of this review was to describe EPCs, their properties and their involvement in several autoimmune diseases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Stem cell reviews and reports - 19(2023), 8 vom: 24. Nov., Seite 2597-2611 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Feugray, Guillaume [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 21.11.2023 Date Revised 26.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s12015-023-10617-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361740603 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361740603 | ||
| 003 | DE-627 | ||
| 005 | 20240126231933.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12015-023-10617-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1271.xml |
| 035 | |a (DE-627)NLM361740603 | ||
| 035 | |a (NLM)37676423 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Feugray, Guillaume |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Endothelial Progenitor Cells in Autoimmune Disorders |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.11.2023 | ||
| 500 | |a Date Revised 26.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. | ||
| 520 | |a Circulating endothelial progenitor cells (EPCs) were first described in 1997 by Asahara et al. as "putative endothelial cells" from human peripheral blood. The study of endothelial progenitors is also intensifying in several pathologies associated with endothelial damage, including diabetes, myocardial infarction, sepsis, pulmonary arterial hypertension, obstructive bronchopneumopathy and transplantation. EPCs have been studied in several autoimmune diseases with endothelial involvement such as systemic lupus erythematosus, thrombotic thrombocytopenic purpura, antineutrophil cytoplasmic antibodies, vasculitis, rheumatoid arthritis, Goujerot-Sjögren and antiphospholipid syndrome. Factors involved in endothelial damage are due to overexpression of pro-inflammatory cytokines and/or autoantibodies. Management of these pathologies, particularly the long-term use of glucocorticoids and methotrexate, promote atherosclerosis. A lack of standardized assessment of the number and function of EPCs represents a serious challenge for the use of EPCs as prognostic markers of cardiovascular diseases (CVD). The objective of this review was to describe EPCs, their properties and their involvement in several autoimmune diseases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a ANCA vasculitis | |
| 650 | 4 | |a Antiphospholipid syndrome | |
| 650 | 4 | |a Autoimmune diseases | |
| 650 | 4 | |a Endothelial progenitor cells | |
| 650 | 4 | |a Rheumatoid arthritis | |
| 650 | 4 | |a Sjögren syndrome | |
| 650 | 4 | |a Systemic lupus erythematosus | |
| 650 | 4 | |a Thrombotic thrombocytopenic purpura | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 700 | 1 | |a Miranda, Sébastien |e verfasserin |4 aut | |
| 700 | 1 | |a Le Cam Duchez, Véronique |e verfasserin |4 aut | |
| 700 | 1 | |a Bellien, Jérémy |e verfasserin |4 aut | |
| 700 | 1 | |a Billoir, Paul |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Stem cell reviews and reports |d 2009 |g 19(2023), 8 vom: 24. Nov., Seite 2597-2611 |w (DE-627)NLM18490143X |x 2629-3277 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2023 |g number:8 |g day:24 |g month:11 |g pages:2597-2611 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12015-023-10617-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2023 |e 8 |b 24 |c 11 |h 2597-2611 | ||